Tags

Type your tag names separated by a space and hit enter

Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma.
J Clin Oncol. 2004 May 15; 22(10):1807-14.JC

Abstract

PURPOSE

Maintenance of telomeres through reactivation of telomerase is a prerequisite for tumors to preserve their ability to proliferate. The purpose of this study was to evaluate telomere length and human telomerase reverse transcriptase (hTERT) expression as markers for progression and prognosis of colorectal carcinoma.

PATIENTS AND METHODS

Telomere length and hTERT expression were analyzed in matched cancer and adjacent noncancer mucosa samples from 57 patients with R0-resected colorectal carcinoma. The median follow-up time was 76 months.

RESULTS

Telomere length and hTERT expression correlated significantly in cancer tissues and adjacent mucosa samples (r = 0.52, P <.001; and r = 0.54, P <.001, respectively). Overall, cancer tissue had shorter telomeres than adjacent mucosa (P <.001). Only in noncancer tissue did telomere length decrease with age (r = 0.36; P <.01). Telomere length in cancer tissue was significantly correlated with tumor stage (P <.01), with longer telomeres in advanced tumors. Patients with ratios of telomere length in cancer to noncancer tissue greater than 0.90 had a significantly poorer overall survival compared with patients with smaller telomere length ratios (P <.002). In multivariate analysis, the telomere length ratio proved to be of independent prognostic value (P <.03).

CONCLUSION

Telomeres in colorectal carcinoma tissue were significantly shorter compared with adjacent normal mucosa as an indication for extensive cell proliferation. The correlation with tumor stage and patient survival suggest that hTERT-mediated telomere stabilization may be critical for progression and prognosis of colorectal carcinoma.

Authors+Show Affiliations

Chirurgische Klinik und Poliklinik, Klinikum rechts der Isar der Technischen Universität München, Munich, Germany. gertler@nt1.chir.med.tu-muenchen.deNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

15143073

Citation

Gertler, Ralf, et al. "Telomere Length and Human Telomerase Reverse Transcriptase Expression as Markers for Progression and Prognosis of Colorectal Carcinoma." Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, vol. 22, no. 10, 2004, pp. 1807-14.
Gertler R, Rosenberg R, Stricker D, et al. Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. J Clin Oncol. 2004;22(10):1807-14.
Gertler, R., Rosenberg, R., Stricker, D., Friederichs, J., Hoos, A., Werner, M., Ulm, K., Holzmann, B., Nekarda, H., & Siewert, J. R. (2004). Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology, 22(10), 1807-14.
Gertler R, et al. Telomere Length and Human Telomerase Reverse Transcriptase Expression as Markers for Progression and Prognosis of Colorectal Carcinoma. J Clin Oncol. 2004 May 15;22(10):1807-14. PubMed PMID: 15143073.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Telomere length and human telomerase reverse transcriptase expression as markers for progression and prognosis of colorectal carcinoma. AU - Gertler,Ralf, AU - Rosenberg,Robert, AU - Stricker,Dominik, AU - Friederichs,Jan, AU - Hoos,Axel, AU - Werner,Martin, AU - Ulm,Kurt, AU - Holzmann,Bernhard, AU - Nekarda,Hjalmar, AU - Siewert,Joerg-Ruediger, PY - 2004/5/15/pubmed PY - 2004/6/4/medline PY - 2004/5/15/entrez SP - 1807 EP - 14 JF - Journal of clinical oncology : official journal of the American Society of Clinical Oncology JO - J Clin Oncol VL - 22 IS - 10 N2 - PURPOSE: Maintenance of telomeres through reactivation of telomerase is a prerequisite for tumors to preserve their ability to proliferate. The purpose of this study was to evaluate telomere length and human telomerase reverse transcriptase (hTERT) expression as markers for progression and prognosis of colorectal carcinoma. PATIENTS AND METHODS: Telomere length and hTERT expression were analyzed in matched cancer and adjacent noncancer mucosa samples from 57 patients with R0-resected colorectal carcinoma. The median follow-up time was 76 months. RESULTS: Telomere length and hTERT expression correlated significantly in cancer tissues and adjacent mucosa samples (r = 0.52, P <.001; and r = 0.54, P <.001, respectively). Overall, cancer tissue had shorter telomeres than adjacent mucosa (P <.001). Only in noncancer tissue did telomere length decrease with age (r = 0.36; P <.01). Telomere length in cancer tissue was significantly correlated with tumor stage (P <.01), with longer telomeres in advanced tumors. Patients with ratios of telomere length in cancer to noncancer tissue greater than 0.90 had a significantly poorer overall survival compared with patients with smaller telomere length ratios (P <.002). In multivariate analysis, the telomere length ratio proved to be of independent prognostic value (P <.03). CONCLUSION: Telomeres in colorectal carcinoma tissue were significantly shorter compared with adjacent normal mucosa as an indication for extensive cell proliferation. The correlation with tumor stage and patient survival suggest that hTERT-mediated telomere stabilization may be critical for progression and prognosis of colorectal carcinoma. SN - 0732-183X UR - https://www.unboundmedicine.com/medline/citation/15143073/Telomere_length_and_human_telomerase_reverse_transcriptase_expression_as_markers_for_progression_and_prognosis_of_colorectal_carcinoma_ L2 - https://ascopubs.org/doi/10.1200/JCO.2004.09.160?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -